0JDI Stock Overview
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ionis Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.33 |
| 52 Week High | US$53.95 |
| 52 Week Low | US$34.98 |
| Beta | 0.40 |
| 1 Month Change | -2.11% |
| 3 Month Change | -18.79% |
| 1 Year Change | 12.73% |
| 3 Year Change | 0.56% |
| 5 Year Change | -50.66% |
| Change since IPO | -21.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0JDI | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -2.4% | -2.3% | -0.7% |
| 1Y | 12.7% | -29.4% | -1.8% |
Return vs Industry: 0JDI exceeded the UK Biotechs industry which returned -29.6% over the past year.
Return vs Market: 0JDI exceeded the UK Market which returned -2.4% over the past year.
Price Volatility
| 0JDI volatility | |
|---|---|
| 0JDI Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0JDI's share price has been volatile over the past 3 months.
Volatility Over Time: 0JDI's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 927 | Brett Monia | www.ionispharma.com |
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus.
Ionis Pharmaceuticals, Inc. Fundamentals Summary
| 0JDI fundamental statistics | |
|---|---|
| Market cap | US$5.96b |
| Earnings (TTM) | -US$366.29m |
| Revenue (TTM) | US$787.65m |
7.6x
P/S Ratio-16.3x
P/E RatioIs 0JDI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0JDI income statement (TTM) | |
|---|---|
| Revenue | US$787.65m |
| Cost of Revenue | US$907.10m |
| Gross Profit | -US$119.45m |
| Other Expenses | US$246.84m |
| Earnings | -US$366.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.51 |
| Gross Margin | -15.17% |
| Net Profit Margin | -46.50% |
| Debt/Equity Ratio | 462.5% |
How did 0JDI perform over the long term?
See historical performance and comparison